AbstractBackgroundIntroduction of new vaccines in low- and lower middle-income countries has accelerated since Gavi, the Vaccine Alliance was established in 2000. This study sought to (i) estimate the costs of introducing pneumococcal conjugate vaccine, rotavirus vaccine and a second dose of measles vaccine in Zambia; and (ii) assess affordability of the new vaccines in relation to Gavi’s co-financing and eligibility policies.MethodsData on ‘one-time’ costs of cold storage expansions, training and social mobilisation were collected from the government and development partners. A detailed economic cost study of routine immunisation based on a representative sample of 51 health facilities provided information on labour and vaccine transport c...
BACKGROUND:In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commit...
IntroductionIn 2016, for the very first time, the Ministry of Health in Zambia implemented a reactiv...
INTRODUCTION: Rotavirus vaccines have the potential to prevent a substantial amount of life-threaten...
AbstractBackgroundIntroduction of new vaccines in low- and lower middle-income countries has acceler...
BACKGROUND: Introduction of new vaccines in low- and lower middle-income countries has accelerated s...
AbstractBackgroundDetailed cost evaluations of delivery of new vaccines such as pneumococcal conjuga...
Background: Detailed cost evaluations of delivery of new vaccines such as pneumococcal conjugate, hu...
BackgroundThe RTS,S/ASO1E malaria vaccine is being piloted in three countries-Ghana, Kenya, and Mala...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
Purpose This study provides a systematic literature review and categorization of the costs reported ...
Abstract Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccin...
AbstractRecent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine in...
Background. The World Health Organization is planning a pilot introduction of a new malaria vaccine ...
Background Vaccines are considered the path out of the COVID-19 pandemic. The government of Kenya is...
Abstract Background Gambia is the second GAVI support-eligible country to introduce the 7-valent pne...
BACKGROUND:In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commit...
IntroductionIn 2016, for the very first time, the Ministry of Health in Zambia implemented a reactiv...
INTRODUCTION: Rotavirus vaccines have the potential to prevent a substantial amount of life-threaten...
AbstractBackgroundIntroduction of new vaccines in low- and lower middle-income countries has acceler...
BACKGROUND: Introduction of new vaccines in low- and lower middle-income countries has accelerated s...
AbstractBackgroundDetailed cost evaluations of delivery of new vaccines such as pneumococcal conjuga...
Background: Detailed cost evaluations of delivery of new vaccines such as pneumococcal conjugate, hu...
BackgroundThe RTS,S/ASO1E malaria vaccine is being piloted in three countries-Ghana, Kenya, and Mala...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
Purpose This study provides a systematic literature review and categorization of the costs reported ...
Abstract Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccin...
AbstractRecent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine in...
Background. The World Health Organization is planning a pilot introduction of a new malaria vaccine ...
Background Vaccines are considered the path out of the COVID-19 pandemic. The government of Kenya is...
Abstract Background Gambia is the second GAVI support-eligible country to introduce the 7-valent pne...
BACKGROUND:In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commit...
IntroductionIn 2016, for the very first time, the Ministry of Health in Zambia implemented a reactiv...
INTRODUCTION: Rotavirus vaccines have the potential to prevent a substantial amount of life-threaten...